QR Code

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression

Rearrangements of the Mixed Lineage Leukemia (MLL/KMT2A) gene are present in approximately 10% of acute leukemias and characteristically define disease with poor outcome. Driven by the unmet need to develop better therapies for KMT2A-rearranged leukemia, we previously discovered that the novel anti-...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Lin Xiao, Mawar Karsa, Emma Ronca, Angelika Bongers, Angelika Kosciolek, Ali El-Ayoubi, Jezrael L. Revalde, Janith A. Seneviratne, Belamy B. Cheung, Laurence C. Cheung, Rishi S. Kotecha, Andrea Newbold, Stefan Bjelosevic, Greg M. Arndt, Richard B. Lock, Ricky W. Johnstone, Andrei V. Gudkov, Katerina V. Gurova, Michelle Haber, Murray D. Norris, Michelle J. Henderson, Klaartje Somers
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Frontiers Media S.A. 2022-05-01
Rangatū:Frontiers in Oncology
Ngā marau:
KMT2A-rearranged leukemia
infant leukemia
curaxin CBL0137
histone deacetylase inhibition
chromatin
Urunga tuihono:https://www.frontiersin.org/articles/10.3389/fonc.2022.863329/full
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite